Article
Dynamic characterization of circulating tumor DNA in HER2-altered advanced non-small cell lung cancer treated with pyrotinib and apatinib: Exploratory biomarker analysis from PATHER2 study.
Lung cancer (Amsterdam, Netherlands) - 1 Feb 2025
Dong Yucheng, Yang Guangjian, Yang Yaning, Zhang Shuyang, Wang Yan, Xu Haiyan
Abstract excerpt
BACKGROUND: HER2 mutations are critical drivers of non-small cell lung cancer (NSCLC), affecting 2 %-3 % of patients and often leads to poor prognosis and limited response to conventional therapies. This study investigates the genomic characteristics and prognostic relevance of dynamic circulating tumor DNA (ctDNA) monitoring in advanced NSCLC patients with HER2 mutations treated with pyrotinib and apatinib....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.